Raltegravir

Drug Profile

Raltegravir

Alternative Names: Isentress; L 900612; MK-0518

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; The French National Agency for Research on AIDS and Viral Hepatitis
  • Class Antiretrovirals; Naphthyridines; Organic chemicals; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for raltegravir in Europe and Japan (Merck Annual report 2016)
  • 01 Dec 2016 Merck completes the phase-III ONCEMRK trial in HIV-1 infections (Combination therapy, Treatment-naive patients) in Italy, Spain, Portugal, Belgium, United Kingdom, Germany, France, Australia, Canada, Chile, USA (PO, 1200mg once daily) (EudraCT2013-001939-47) (NCT02131233)
  • 25 Oct 2016 Preregistration for HIV-1 infections (Combination therapy, Treatment-naive) in USA (PO) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top